LSE:AZNPharmaceuticals
AstraZeneca (LSE:AZN) Unveils Promising Phase III Results For Baxdrostat In Hypertension Trial
AstraZeneca (LSE:AZN) recently experienced a weekly price move of 2% amid announcements that could have supported its momentum. The successful Phase III trial results for Baxdrostat, targeting a significant global need for hypertension treatments, likely provided a positive catalyst. Additionally, the European Union's approval of Imfinzi for a new cancer indication may have added further support. These developments occurred against a backdrop of flat overall market performance, with major...